Characterizing the tumor microenvironment at the single-cell level reveals the potential immune evasion mechanism in giant cell tumor of bone
The role of Siglec15 in tumor immunosuppression and osteolytic destruction was determined, and validated with recombinant Siglec15 antibody, and the results broaden the understanding of the immune-microenvironment of GCTB, and provide a new insight for reducing the recurrence by adjuvant therapy.